B. Konicek

发表

Targeting the eukaryotic translation initiation factor 4E for cancer therapy.

J. Graff, J. H. Carter, B. Konicek, 2008, Cancer research.

AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon.

Z. Lu, G. Sandusky, J. Graff, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Antisense oligonucleotide targeting eukaryotic translation initiation factor 4E reduces growth and enhances chemosensitivity of non-small-cell lung cancer cells

R. Kratzke, J. Graff, A. Sadiq, 2015, Cancer Gene Therapy.

Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors

D. Timm, R. Walgren, P. Ebert, 2018, Oncotarget.

Targeting the eIF4F translation initiation complex for cancer therapy

J. Graff, B. Konicek, Chad A. Dumstorf, 2008, Cell cycle.

Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus.

X. Xia, F. Rauscher, B. Konicek, 1993, The Journal of biological chemistry.

Therapeutic Discovery Modulation of 4 EBP 1 Function as a Critical Determinant of Enzastaurin-Induced Apoptosis

N. Sonenberg, J. Graff, L. Furic, 2010 .

Integrin-linked kinase expression increases with prostate tumor grade.

J. Deddens, J. Graff, J. H. Carter, 2001, Clinical Cancer Research.

Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases.

N. Sonenberg, J. Pelletier, P. Iversen, 2011, Cancer research.

Integrin-linked Kinase Expression Increases with Prostate Tumor Grade 1

J. Deddens, J. Graff, J. H. Carter, 2001 .

Regulation of mouse colony-stimulating factor-1 gene promoter activity by AP1 and cellular nucleic acid-binding protein.

T. Rajavashisth, X. Xia, B. Konicek, 1998, DNA and cell biology.

Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry

R. Burge, B. Lockshin, B. Zhu, 2022, Dermatology and Therapy.

Binding of a CTF/NF1-like protein to the mouse colony-stimulating factor-1 gene promoter.

X. Xia, B. Konicek, M. Harrington, 1995, DNA and cell biology.

Increased AKT Activity Contributes to Prostate Cancer Progression by Dramatically Accelerating Prostate Tumor Growth and Diminishing p27Kip1 Expression*

R. Vessella, G. Sandusky, J. Graff, 2000, The Journal of Biological Chemistry.

Targeting Eukaryotic Translation in Mesothelioma Cells with an eIF4E-Specific Antisense Oligonucleotide

R. Kratzke, J. Graff, B. Jacobson, 2013, PloS one.

eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival.

J. Deddens, J. Graff, J. H. Carter, 2009, Cancer research.

Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity.

Tao Wang, Hong Zhang, N. Dean, 2007, The Journal of clinical investigation.

Modulation of 4E-BP1 Function as a Critical Determinant of Enzastaurin-Induced Apoptosis

Nahum Sonenberg, N. Sonenberg, J. Graff, 2010, Molecular Cancer Therapeutics.

The Protein Kinase Cβ–Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma Xenografts

R. Campbell, P. Iversen, J. Graff, 2005 .

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

J. Graff, R. Walgren, C. Shih, 2012, Investigational New Drugs.

Expression of group IIa secretory phospholipase A2 increases with prostate tumor grade.

J. Deddens, J. Graff, J. H. Carter, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors.

P. Iversen, L. Platanias, J. Graff, 2013, Blood.

Pharmacogenetic Inhibition of eIF4E-Dependent Mmp9 mRNA Translation Reverses Fragile X Syndrome-like Phenotypes

Christos G. Gkogkas, K. Nader, J. Lacaille, 2014, Cell reports.

The Progression of LNCaP Human Prostate Cancer Cells to Androgen Independence Involves Decreased FOXO3a Expression and Reduced p27KIP1 Promoter Transactivation

J. Graff, B. Neubauer, B. Konicek, 2005, Molecular Cancer Research.

MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping

R. Walgren, J. Manro, V. Wacheck, 2017, Investigational New Drugs.

IL17A blockade with ixekizumab suppresses MuvB signaling in clinical psoriasis.

N. McKenna, S. Ochsner, E. Dow, 2023, The Journal of investigative dermatology.

Transcriptional regulation of the mouse CSF‐1 gene

B. Konicek, X. Xia, M. Harrington, 1997, Molecular reproduction and development.

Development of Psoriasis Assessment Tools Among Patients in the CorEvitas Psoriasis Registry

R. Burge, W. Gulliver, C. Leonardi, 2023, Journal of Psoriasis and Psoriatic Arthritis.

Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases.

N. Sonenberg, J. Pelletier, P. Iversen, 2011, Cancer research.